Apobec3b and cd274 as combined biomarkers for predicting response to immunotherapy in urothelial carcinoma of the bladder

HIGHLIGHTS

  • who: Chuanhao Zhang et al. from the Graduate School Dalian University, Dalian, China have published the research work: APOBEC3B and CD274 as Combined Biomarkers for Predicting Response to Immunotherapy in Urothelial Carcinoma of the Bladder, in the Journal: Journal of Oncology of 24/09/2022
  • what: The findings this study provide valuable insights for precision medicine. This study demonstrated that the combined biomarker of APOBEC3B and CD274 was more effective in predicting the response to PD-1/PD-L1 inhibitors than a single biomarker of CD274 in bladder urothelial carcinoma.
  • how: The results . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?